Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Fateh

Showing results (111-120 of 148) with videos related to

Pageof 15
Sort By:
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|October 1, 1993
Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancerP Stieber, H Dienemann, U Hasholzner, et al.
Cancer|November 15, 1991
Histologic, biochemical, and clinical parameters for monitoring multiple myelomaR Bartl, B Frisch, H Diem, et al.
American Journal of Clinical Pathology|July 1, 1996
Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulinC M Schambeck, R Bartl, W Höchtlen-Vollmar, et al.
Haematology and Blood Transfusion|January 1, 1977
Enzymecytochemical and immunocytological studies as a basis for the revaluation of the histology of cutaneous B-cell and T-cell lymphomasG Burg, H Rodt, H Grosse-Wilde, et al.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|March 1, 1994
Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre studyW Ebert, H Dienemann, A Fateh-Moghadam, et al.
Anticancer Research|November 1, 1996
Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancerP Stieber, N Schmeller, C Schambeck, et al.
Neurology|October 1, 1983
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severityU A Besinger, K V Toyka, M Hömberg, et al.
Anticancer Research|July 1, 1997
Screening for prostatic carcinoma with prostate specific antigenR Waidelich, H M Jansen, P Stieber, et al.
Klinische Wochenschrift|January 2, 1980
Plasma-separation in myasthenia gravis: a new method of rapid plasma exchangeW Samtleben, U A Besinger, K V Toyka, et al.
Genes and Immunity|July 14, 2017
EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis CM Asnavandi, M Zargar, F Vaziri, et al.
Pageof 15

Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|October 1, 1993
Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancerP Stieber, H Dienemann, U Hasholzner, et al.
Cancer|November 15, 1991
Histologic, biochemical, and clinical parameters for monitoring multiple myelomaR Bartl, B Frisch, H Diem, et al.
American Journal of Clinical Pathology|July 1, 1996
Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulinC M Schambeck, R Bartl, W Höchtlen-Vollmar, et al.
Haematology and Blood Transfusion|January 1, 1977
Enzymecytochemical and immunocytological studies as a basis for the revaluation of the histology of cutaneous B-cell and T-cell lymphomasG Burg, H Rodt, H Grosse-Wilde, et al.
European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies|March 1, 1994
Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre studyW Ebert, H Dienemann, A Fateh-Moghadam, et al.
Anticancer Research|November 1, 1996
Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancerP Stieber, N Schmeller, C Schambeck, et al.
Neurology|October 1, 1983
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severityU A Besinger, K V Toyka, M Hömberg, et al.
Anticancer Research|July 1, 1997
Screening for prostatic carcinoma with prostate specific antigenR Waidelich, H M Jansen, P Stieber, et al.
Klinische Wochenschrift|January 2, 1980
Plasma-separation in myasthenia gravis: a new method of rapid plasma exchangeW Samtleben, U A Besinger, K V Toyka, et al.
Genes and Immunity|July 14, 2017
EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis CM Asnavandi, M Zargar, F Vaziri, et al.
Pageof 15